BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28033223)

  • 1. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
    Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
    Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of
    Raveenthiran S; Esler R; Yaxley J; Kyle S
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2280-2288. PubMed ID: 31332498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma.
    Sasikumar A; Joy A; Nanabala R; Unni M; Tk P
    Clin Nucl Med; 2016 Dec; 41(12):e517-e519. PubMed ID: 27749421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
    Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance of
    Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
    Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
    Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT.
    Lawhn-Heath C; Flavell RR; Glastonbury C; Hope TA; Behr SC
    Clin Nucl Med; 2017 Apr; 42(4):e218-e220. PubMed ID: 28166149
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
    Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
    Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
    Einspieler I; Tauber R; Maurer T; Schwaiger M; Eiber M
    Clin Nucl Med; 2016 May; 41(5):e261-2. PubMed ID: 26859205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of
    Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic potential of PET/CT using a
    Sawicki LM; Buchbender C; Boos J; Giessing M; Ermert J; Antke C; Antoch G; Hautzel H
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):102-107. PubMed ID: 26996777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.